For now, there’s no hard and fast rule when it comes to the slippery slope CBD companies will have to contend with until the FDA starts approving products. Until then, it’s best to err on the side of caution and avoid making any claims you can’t back up with hard science and cited studies, lest draw the ire of government officials who can and will put you out of business if you don’t heed their warnings.
Three days in Philadelphia, September 25 to 27, with a free record-clearing clinic and a…
Four decades after its Amsterdam beginnings, Barney’s Farm is marking the milestone with new markets,…
Gallup’s new numbers hold a small, awkward pattern: the Americans most convinced cannabis is bad…
The FDA is seeking outside data and analytics services to better understand how people use…
Male cannabis and hemp plants release huge quantities of it in mid-to-late summer, which happens…
Buried in a 50-page legal brief filed August 17 with a DEA administrative law judge…